Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 9, 2010

Ambry Confirmed as First U.S. CSP for NimbleGen Sequence-Capture Solution

  • Ambry Genetics has become the first Certified Service Provider (CSP) in the U.S. for NimbleGen's SeqCap EZ Exome sequence-capture technology. Status as a CSP means Ambry will be able to offer target-enrichment services using the SeqCap EZ Human Exome coupled with next-gen sequencing services for genetic research.
    The workflow will involve processing customer gDNA samples for genomic enrichment using 2.1 million optimized DNA probes from SeqCap EZ Exome, in order to capture all human coding exons, followed by sequencing using short-read, paired-end technology.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »